Category Archives: Indian Patent Law

Eli Lilly bats for a favourable patent regime in India

Eli Lilly wants a more favourable patent regime that ‘rewards innovation’ and would welcome an open dialogue from the government in this respect New Delhi: Global pharma company Eli Lilly wants a more favourable patent regime in India that “rewards … Continue reading

Posted in Indian Patent Law, Innovation, Special 301 report, Uncategorized | Leave a comment

Pharma company Viiv’s attempt to secure patents for key HIV drugs dolutegravir and cabotegravir opposed in India

‘Patent opposition’ seeks to ensure availability of affordable generics New Delhi/Geneva, 8 February, 2016—People living with HIV have opposed patent applications in India for two important HIV medicines, dolutegravir and cabotegravir.  Médecins Sans Frontières/ Doctors Without Borders (MSF) supports these … Continue reading

Posted in Evergreening, Indian Patent Law, Patent Opposition, Uncategorized | Leave a comment

The pill that costs $9,000 in US sells for $70 in India

Rema Nagarajan, TNN | Feb 7, 2016 And that’s just one leukaemia drug. India’s generic industry has been producing many such life-saving medicines at a fraction of the global price The Hyderabad-based Bharat Biotech might be the first to come out … Continue reading

Posted in Hepatitis C, Indian Patent Law, Sofosbuvir, Uncategorized | Leave a comment

Why India must beware the side-effects of Pacific Treaty

December 30, 2015, The Hindu Businessline | ARCHANA JATKAR The scope of the recently concluded Trans-Pacific Partnership Agreement (TPPA) goes well beyond conventional trade concerns. It includes extensive obligations on intellectual property (IP) exceeding the minimum standards of the World … Continue reading

Posted in Patent linkage, Patent Term Extension, Sec 3 (d), TPP, TRIPS flexibilities, Uncategorized | Leave a comment

No respite for Big Pharma on patents

FINANCIAL EXPRESS| By Banikinkar Pattanayak on December 30, 2015 Dilution of Section 3(d), compulsory licensing unlikely despite US concerns Disappointed with India’s new National IPR Policy, the US has upped the ante for a world-class patenting regime in India, but … Continue reading

Posted in Compulsory Licensing, IPR policy, Sec 3 (d), TRIPS, TRIPS plus, US pressure on India | Tagged , , , , , | Leave a comment

Delhi HC upholds Roche’s patent claims on Tarceva against Cipla

Economic Times, November 28, 2015. Mumbai – A division bench of the Delhi High Court sided with Roche against Indian firm Cipla, upholding the Swiss drug maker’s patent claims on key lung cancer drug erlotinib hydrochloride, branded Tarceva. The ruling is … Continue reading

Posted in Cancer, Patent infringement, Sec 3 (d) | Leave a comment

Drug patenting in India: looking back and looking forward

Nature reviews. By Bhaven N. Sampat and Kenneth C. Shadlen. Patent protection for drugs in India has been a contentious issue in recent years, with several high-profile denials of patents — for example, for Novartis’ anticancer drug imatinib mesylate (Glivec; also … Continue reading

Posted in Indian Patent Law, Patents, Sec 3 (d) | Leave a comment